Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

U.S. Personal Products Industry Analysis

UpdatedJun 28, 2026
DataAggregated Company Financials
Companies108
  • 7D1.0%
  • 3M12.7%
  • 1Y-16.5%
  • YTD-9.4%

The Personal Products is pretty flat in the last 7 days, but Kenvue has stood out, gaining 5.6%. As for the longer term, the industry has declined 17% in the last year. Looking forward, earnings are forecast to grow by 32% annually.

Industry Valuation and Performance

Has the U.S. Personal Products Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Sun, 28 Jun 2026US$84.0bUS$48.3bUS$693.8m17.3x121.1x1.7x
Tue, 26 May 2026US$80.8bUS$48.4bUS$753.3m15.7x107.2x1.7x
Thu, 23 Apr 2026US$77.7bUS$48.1bUS$614.6m22.6x126.4x1.6x
Sat, 21 Mar 2026US$80.8bUS$48.2bUS$678.5m21.5x119.1x1.7x
Mon, 16 Feb 2026US$93.8bUS$48.0bUS$846.8m22.5x110.8x2x
Wed, 14 Jan 2026US$92.9bUS$47.6bUS$350.3m21.7x265.2x2x
Fri, 12 Dec 2025US$91.3bUS$47.6bUS$351.2m23.2x260x1.9x
Sun, 09 Nov 2025US$83.1bUS$47.5bUS$491.5m20.6x169.1x1.8x
Tue, 07 Oct 2025US$88.1bUS$47.7bUS$307.3m20.1x286.6x1.8x
Thu, 04 Sep 2025US$100.6bUS$47.6bUS$303.6m22.1x331.4x2.1x
Sat, 02 Aug 2025US$101.6bUS$48.1bUS$113.1m20.7x897.5x2.1x
Mon, 30 Jun 2025US$96.7bUS$48.0bUS$109.4m17.5x883.9x2x
Wed, 28 May 2025US$93.8bUS$48.0bUS$113.4m18.4x827.5x2x
Fri, 25 Apr 2025US$85.3bUS$48.7bUS$549.4m21.7x155.2x1.8x
Sun, 23 Mar 2025US$91.0bUS$48.7bUS$378.1m28.1x240.7x1.9x
Tue, 18 Feb 2025US$90.8bUS$49.0bUS$335.7m23.9x270.4x1.9x
Thu, 16 Jan 2025US$95.8bUS$49.3bUS$1.5b26.3x64.9x1.9x
Sat, 14 Dec 2024US$103.6bUS$49.3bUS$1.5b29.1x70.1x2.1x
Mon, 11 Nov 2024US$98.2bUS$49.3bUS$1.5b27.3x66.8x2x
Wed, 09 Oct 2024US$107.5bUS$49.5bUS$1.6b25.9x66.5x2.2x
Fri, 06 Sep 2024US$110.0bUS$49.5bUS$1.6b21x67.2x2.2x
Sun, 04 Aug 2024US$105.2bUS$48.9bUS$2.5b22.9x42.6x2.2x
Tue, 02 Jul 2024US$111.3bUS$49.0bUS$2.4b21.3x45.9x2.3x
Thu, 30 May 2024US$118.1bUS$49.0bUS$2.4b20.3x48.7x2.4x
Sat, 27 Apr 2024US$125.7bUS$48.8bUS$2.5b24.6x49.5x2.6x
Mon, 25 Mar 2024US$130.8bUS$48.8bUS$2.5b24.6x52.5x2.7x
Wed, 21 Feb 2024US$127.1bUS$49.2bUS$2.5b30.1x50.7x2.6x
Fri, 19 Jan 2024US$123.0bUS$50.1bUS$2.6b27.1x48.2x2.5x
Sun, 17 Dec 2023US$127.2bUS$49.9bUS$2.6b27.1x48.3x2.5x
Tue, 14 Nov 2023US$105.8bUS$49.9bUS$2.7b23.8x39.4x2.1x
Thu, 12 Oct 2023US$118.0bUS$50.0bUS$3.3b24.3x36x2.4x
Sat, 09 Sep 2023US$129.9bUS$50.0bUS$3.3b19.8x39.6x2.6x
Mon, 07 Aug 2023US$142.8bUS$49.9bUS$3.1b25.9x46x2.9x
Wed, 05 Jul 2023US$154.4bUS$49.3bUS$3.1b22.7x49.2x3.1x
Price to Earnings Ratio

49.2x


Total Market Cap: US$154.4bTotal Earnings: US$3.1bTotal Revenue: US$49.3bTotal Market Cap vs Earnings and Revenue0%0%0%
U.S. Personal Products Industry Price to Earnings3Y Average 172.7x202420252026
Current Industry PE
  • Investors are pessimistic on the American Personal Products industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 121x which is lower than its 3-year average PE of 173x.
  • The 3-year average PS ratio of 2.1x is higher than the industry's current PS ratio of 1.7x.
Past Earnings Growth
  • The earnings for companies in the Personal Products industry have declined 40% per year over the last three years.
  • Meanwhile revenues have remained mostly flat.
  • This means that although sales have remained flat, either the cost of doing business or the level of investment back into businesses has increased, which has decreased profits.

Industry Trends

Which industries have driven the changes within the U.S. Consumer Staples industry?

US Market-2.52%
Consumer Staples1.13%
Personal Products1.00%
Personal Products1.00%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
KVUE KenvueUS$19.135.6%
+US$1.9b		-8.4%PE22.6x
IPAR InterparfumsUS$107.979.0%
+US$284.4m		-18.1%PE20.4x
BRBR BellRing BrandsUS$11.5522.1%
+US$243.0m		-80.3%PE8.5x
EPC Edgewell Personal CareUS$27.7219.9%
+US$212.4m		19.2%PS0.6x
ELF e.l.f. BeautyUS$67.435.0%
+US$192.0m		-46.6%PE152.3x

Latest News

BRBR
US$11.55
BellRing Brands
7D
22.1%
1Y
-80.3%
ODD
US$14.86
Oddity Tech
7D
13.7%
1Y
-80.2%
HLF
US$12.54
Herbalife
7D
5.4%
1Y
43.6%
MED
US$10.51
Medifast
7D
-4.8%
1Y
-22.5%
Narrative Update • Jun 25

MED: Leadership Transition And Higher Future P/E Will Support Upside Potential

Analysts have modestly adjusted their price target on Medifast, reflecting updated assumptions for discount rate, revenue trends, profit margins, and a higher future P/E multiple. These factors together temper near-term earnings expectations while slightly lifting the valuation framework in dollar terms.
KVUE
US$19.13
Kenvue
7D
5.6%
1Y
-8.4%
Narrative Update • Jun 24

KVUE: Future Returns Will Balance Kimberly-Clark Deal Timing And Execution Risks

Kenvue's analyst price target has been trimmed by $1 as analysts factor in updated discount rate assumptions and peer commentary that shifts more upside toward related deals in later years. Analyst Commentary Recent commentary around Kenvue highlights a split view, with some analysts focusing on the potential value of its connection to Kimberly-Clark over time, while others are trimming near term expectations and adjusting discount rate assumptions.
COTY
US$1.92
Coty
7D
-1.5%
1Y
-58.4%
EPC
US$27.72
Edgewell Personal Care
7D
19.9%
1Y
19.2%
ELF
US$67.43
e.l.f. Beauty
7D
5.0%
1Y
-46.6%
EL
US$80.54
Estée Lauder Companies
7D
-5.0%
1Y
0.6%
IPAR
US$107.97
Interparfums
7D
9.0%
1Y
-18.1%
Analysis Article • Jun 19

Interparfums (IPAR) Stock Could Be 9.4% Undervalued After Institutional Buying

Interparfums (IPAR) is back in focus after recent data showed institutional investors now hold 66.49% of the company, with largest shareholder Chuck Royce significantly increasing his position last quarter. See our latest analysis for Interparfums. Interparfums’ recent 1 month share price return of 9.77% and 3 month share price return of 10.15%, taking the stock to US$99.09, contrast with a 1 year total shareholder return that declined 22.5%. This suggests improving short term momentum after...
USNA
US$20.70
USANA Health Sciences
7D
9.6%
1Y
-33.5%
Seeking Alpha • Jun 19

USANA Health Sciences: How The Restructuring Plan Makes It A Strong Buy

Summary USANA Health Sciences is undergoing restructuring, causing temporary margin pressure but positioning for significant future profit expansion. Rise Wellness posted 740% revenue growth, but gross margin fell to 7.1% due to promotional discounts; margin recovery is expected as restocking begins at regular prices. Hiya's revenue dropped 13.3% amid higher CAC from Meta algorithm changes; in-house manufacturing should drive cost savings in H2. I assign USNA a Buy rating with a $30.8/share target, citing undervaluation (1.92x forward EV/EBITDA) and strong cash position. Read the full article on Seeking Alpha
HNST
US$3.60
Honest Company
7D
-4.5%
1Y
-26.2%
Narrative Update • Jun 16

HNST: Improving Margins And Buybacks Will Support Future Stock Re Rating

The Honest Company stock price target has been adjusted modestly higher, with analysts citing updated valuation work that reflects a slightly different discount rate, revenue outlook, profit margin profile, and future P/E assumptions consistent with recent target increases of $0.40, $0.50, and $1.00 from Street research. Analyst Commentary Recent price target revisions for Honest Company stock point to a more constructive tone from bullish analysts, who are updating models to reflect refreshed assumptions around growth, profitability, and P/E levels rather than any single short term event.
NAGE
US$3.42
Niagen Bioscience
7D
-2.3%
1Y
-75.9%
Narrative Update • Jun 16

NAGE: Injectables And Expanded Clinical Access Will Support Future Buyback Upside

Niagen Bioscience's analyst price target has been reduced by a combined $5 across recent reports as analysts factor in updated assumptions on discount rates, revenue growth, profit margins and future P/E multiples, while maintaining a fair value estimate of $12.60. Analyst Commentary Recent research on Niagen Bioscience highlights a mix of optimism about the company’s long term potential and caution around the assumptions that underpin the current fair value estimate of $12.60.
WALD
US$1.46
Waldencast
7D
-12.0%
1Y
-43.8%
Narrative Update • Jun 15

WALD: Obagi Sale And Injectables Launch Will Support Future Upside

Analysts have lifted their price target on Waldencast stock to $3.00 from $2.50, citing the agreed sale of the Obagi skin care and aesthetics business for up to $460m and the view that current valuation does not fully reflect the strength of Obagi, Milk and the upcoming Saypha injectables launch. Analyst Commentary Bullish analysts see the agreed sale of the Obagi skin care and aesthetics business and the ongoing investment in Saypha injectables as key supports for the recent reset to a $3.00 price target.
BHST
US$2.77
BioHarvest Sciences
7D
-15.0%
1Y
-58.7%